We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+24.68%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.51B
AUM Growth
+$758M
Cap. Flow
+$605M
Cap. Flow %
17.25%
Top 10 Hldgs %
47.4%
Holding
285
New
108
Increased
67
Reduced
35
Closed
69

Top Buys

Rank Stock Value
1
IMDX
Insight Molecular Diagnostics
IMDX
+$28.2M
2
ALGN icon
Align Technology
ALGN
+$19.3M
3
APR
Apria, Inc. Common Stock
APR
+$17.3M
4
CUTR
Cutera, Inc.
CUTR
+$14.8M
5
CMIIU
CM Life Sciences II Inc. Unit
CMIIU
+$13M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$14.4M
2
AFIB
Acutus Medical Inc
AFIB
+$13.5M
3
SHC icon
Sotera Health
SHC
+$12.9M
4
OPCH icon
Option Care Health
OPCH
+$12.1M
5
BNGO icon
Bionano Genomics
BNGO
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 33%
2 Industrials 1.49%
3 Materials 0.46%
4 Financials 0.45%
5 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
201
DELISTED
KalVista Pharmaceuticals
KALV
$520K 0.01%
+20,257
New +$532K
BCAB icon
202
BioAtla
BCAB
$5.61M
$457K 0.01%
180
-1,346
-88% -$3.45M
FOLD
203
DELISTED
Amicus Therapeutics
FOLD
$450K 0.01%
45,525
-12,675
-22% -$196K
ACGN
204
PUT
DELISTED
Aceragen Inc
ACGN
$434K 0.01%
+19,655
New +$1.47M
MAPSW
205
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$352K 0.01%
50,000
– –
MREO
206
Mereo BioPharma
MREO
$48.3M
$339K 0.01%
+100,514
New +$355K
IRD
207
Opus Genetics
IRD
$313M
$334K 0.01%
+57,536
New +$535K
INO icon
208
PUT
Inovio Pharmaceuticals
INO
$79.6M
$300K 0.01%
+2,692
New +$354K
NKTX icon
209
Nkarta
NKTX
$171M
$261K 0.01%
7,919
-12,081
-60% -$577K
SVRA icon
210
Savara
SVRA
$1.17B
$208K 0.01%
+100,000
New +$171K
ACGN
211
CALL
DELISTED
Aceragen Inc
ACGN
$208K 0.01%
+9,421
New +$706K
TCACU
212
DELISTED
Tuatara Capital Acquisition Corporation Unit
TCACU
$200K 0.01%
+20,000
New +$204K
CHAQ.WS
213
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
$145K ﹤0.01%
+153,960
New +$170K
ABBV icon
214
PUT
AbbVie
ABBV
$440B
– –
-100,000
Closed -$10.7M
ACRS icon
215
CALL
Aclaris Therapeutics
ACRS
$860M
– –
-100,000
Closed -$647K
APVO icon
216
Aptevo Therapeutics
APVO
$5.31M
– –
0
– -$301K
BCRX icon
217
BioCryst Pharmaceuticals
BCRX
$2.71B
– –
-412,419
Closed -$3.07M
BLFS icon
218
BioLife Solutions
BLFS
$1.71B
– –
-150,000
Closed -$5.98M
CNC icon
219
CALL
Centene
CNC
$33.1B
– –
-50,000
Closed -$3M
CRDF icon
220
Cardiff Oncology
CRDF
$77.1M
– –
-100,000
Closed -$1.8M
CRIS icon
221
Curis
CRIS
$3.49M
– –
-1,386
Closed -$5.8M
DCTH icon
222
Delcath Systems
DCTH
$594M
– –
-65,000
Closed -$1.17M
DGX icon
223
PUT
Quest Diagnostics
DGX
$26.2B
– –
-130,000
Closed -$15.5M
ELV icon
224
PUT
Elevance Health
ELV
$86.6B
– –
-30,000
Closed -$9.63M
EOLS icon
225
CALL
Evolus
EOLS
$536M
– –
-200,000
Closed -$672K
7 8
9
10 11

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2021 Portfolio in Review

As of Q1 2021, Pura Vida Investments held 285 positions worth $3.51B, up 28% from $2.75B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Pura Vida Investments deployed $605M of net new capital in Q1 2021, opening 108 new positions and adding to 67 existing holdings. Its largest new stake was Align Technology: 35,000 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was Vericel Corp, an estimated $14.4M trimmed.

  • Pura Vida Investments's largest Q1 2021 buy was Align Technology: 35,000 shares worth $19M.
  • Pura Vida Investments added most to Insight Molecular Diagnostics in Q1 2021, an estimated $28.2M increase.
  • Pura Vida Investments's biggest Q1 2021 reduction was Vericel Corp, cutting an estimated $14.4M.
  • Pura Vida Investments fully exited Acutus Medical Inc in Q1 2021, selling an estimated $13.5M.
  • Pura Vida Investments's ten largest holdings make up 47% of its $3.51B portfolio in Q1 2021.
  • Pura Vida Investments opened 108 new positions and closed 69 in Q1 2021.
  • Pura Vida Investments's portfolio value rose 28% quarter-over-quarter to $3.51B.

Based on Pura Vida Investments's 13F filing for Q1 2021, filed 12 May 2021.